艾比普罗 (EpiPro) 是一种新的,合成的,活动调节的促进剂,它针对患者的过活神经元,用于基因疗法应用
Cassidy T Burke1, Iuliia Vitko1, Justyna Straub1
1Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
International journal of molecular sciences
|October 14, 2023
概括
研究人员设计了EpiPro,一种用于的基因治疗的新型促进剂. EpiPro驱动过度活跃的神经元中的基因表达,通过向与有关的遗传变化来治疗,显示出治疗的前景.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 生包括神经元过活和改变的基因转录.
- 活动依赖的转录因子在慢性中被上调.
研究的目的:
- 设计和验证一种新的特异性促进剂 (EpiPro).
- 在动物模型中评估EpiPro的活性依赖性和表达.
主要方法:
- 具有相关转录因子的结合点的EpiPro促进体构造.
- 在动物模型中进行电生理学和GFP表达分析 (/皮洛卡尔宾,电火点燃).
- 在后评估EpiPro激活时间过程.
主要成果:
- 埃皮普罗在过度活跃的神经元中驱动GFP表达,在状态后增加150倍.
- 在慢性模型中观察到持续的GFP表达,特别是在牙状颗粒细胞中.
- 后的EpiPro激活速度很快,并在几周内逐渐下降.
结论:
- 埃皮普罗是一种有效的特异性促进剂,对神经元活动有反应.
- 研究结果支持"牙状门的破裂"假设在边缘性发症.
- 埃皮普罗证明了作为治疗的基因治疗驱动器的潜力.
更多相关视频
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.7K
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.1K
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
